Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot bone damage in multiple myeloma

NCT ID NCT02800954

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy controls. The goal was to see if M-CSF could serve as a new marker for bone damage, which is a common complication of myeloma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If M-CSF levels prove useful, it could lead to a simple blood test to detect bone damage in multiple myeloma patients earlier.
What could go wrong
This is a small, completed observational study, not a treatment trial. The marker may not be reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

111 people

The number who actually took part.

Started

Feb 2009

Finished

Jul 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For the multiple myeloma group * confirmed diagnosis of de novo multiple myeloma according to the International Myeloma Working Group criteria * bisphosphonate therapy for more than 60 days, * signature of the informed consent form, * patients over the age of 18 years. For the monoclonal gammopathy of undetermined significance (MGUS) group * confirmed diagnosis of MGUS according to the International Myeloma Working Group criteria * signature of the informed consent form, * patients over the age of 18 years. For the healthy control group * signature of the informed consent form, * subjects over the age of 18 years. Exclusion Criteria: * patients with thyroid or parathyroid disease, * osteomalacia, rheumatoid arthritis, Paget's disease, osteoporosis, * bisphosphonate therapy for less than 60 days, * absence of informed consent, * patients under the age of 18 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Monoclonal gammopathy of undetermined significance are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monoclonal gammopathy of uncertain significance plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • CH Beauvais

    Beauvais, 60021, France

  • CHU Amiens

    Amiens, 80054, France

  • Ch Saint Quentin

    Saint-Quentin, 02321, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.